Literature DB >> 24284228

Effect of Allium macrostemon on a rat model of depression studied by using plasma lipid and acylcarnitine profiles from liquid chromatography/mass spectrometry.

Shili Chen1, Cong Wei2, Peng Gao1, Hongwei Kong1, Zhenhua Jia2, Chunxiu Hu1, Weidong Dai1, Yiling Wu3, Guowang Xu4.   

Abstract

The present study aimed to investigate the anti-depressive effect of the traditional Chinese medicine Allium macrostemon in a rat model of depression induced by exposure to chronic immobilization stress. Lipid and acylcarnitine metabolism were set into the focus of this study due to their key role in the pathogenesis of depression. Plasma lipid profiling was performed by ultra fast liquid chromatography/ion trap-time of flight mass spectrometry. Ultra-high performance liquid chromatography/triple quadrupole mass spectrometry was used to characterize the plasma acylcarnitine profile. Principal component analysis (PCA) revealed distinct differences in plasma lipid and acylcarnitine profiles of depressed rats from those in the control rats, which were also validated by univariate analysis. Several lysophosphatidylcholines (LPC (18:1→:2), LPC (20:1), LPC (O-16:2), and LPC (O-18:3)) as well as most medium- and long-chain acylcarnitines were elevated, while some phosphatidylcholines (PC (32:1), PC (36:4→:5), PC (37:4), PC (38:4→:6), PC (40:6), PC (O-36:4), and PC (O-38:5)) and triglycerides (TG (58:12), TG (60:12), and TG (62:13→:14)) were decreased in the plasma of depressed rats. These changes indicate that depressed rats were associated with inflammatory conditions and an incomplete β-oxidation of fatty acids. Most of these dysregulated metabolites were returned to their normal levels after treatment with A. macrostemon according to PCA and univariate analysis, highlighting the anti-depressive effect of this traditional Chinese medicine. These results show that liquid chromatography/mass spectrometry-based quantitative metabolic profiling method is a useful tool to investigate the metabolic changes in depression and the anti-depressive effect of traditional Chinese medicine.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acylcarnitine; Allium macrostemon; Depression; Lipidomics; Liquid chromatography–mass spectrometry

Mesh:

Substances:

Year:  2013        PMID: 24284228     DOI: 10.1016/j.jpba.2013.10.045

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  10 in total

1.  Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.

Authors:  Ahmed T Ahmed; Siamak MahmoudianDehkordi; Sudeepa Bhattacharyya; Matthias Arnold; Duan Liu; Drew Neavin; M Arthur Moseley; J Will Thompson; Lisa St John Williams; Gregory Louie; Michelle K Skime; Liewei Wang; Patricio Riva-Posse; William M McDonald; William V Bobo; W Edward Craighead; Ranga Krishnan; Richard M Weinshilboum; Boadie W Dunlop; David S Millington; A John Rush; Mark A Frye; Rima Kaddurah-Daouk
Journal:  J Affect Disord       Date:  2019-11-30       Impact factor: 4.839

2.  Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia.

Authors:  Xuan Wang; Meihong Xiu; Keqiang Wang; Xiuru Su; Xirong Li; Fengchun Wu
Journal:  Metabolomics       Date:  2022-07-11       Impact factor: 4.747

3.  Blocking of carnitine palmitoyl transferase 1 potently reduces stress-induced depression in rat highlighting a pivotal role of lipid metabolism.

Authors:  Anne Skøttrup Mørkholt; Ove Wiborg; Jette G K Nieland; Søren Nielsen; John Dirk Nieland
Journal:  Sci Rep       Date:  2017-05-19       Impact factor: 4.379

4.  Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment.

Authors:  Sudeepa Bhattacharyya; Boadie W Dunlop; Siamak Mahmoudiandehkordi; Ahmed T Ahmed; Gregory Louie; Mark A Frye; Richard M Weinshilboum; Ranga R Krishnan; A John Rush; Helen S Mayberg; W Edward Craighead; Rima Kaddurah-Daouk
Journal:  Front Neurosci       Date:  2019-09-12       Impact factor: 4.677

5.  Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.

Authors:  Siamak MahmoudianDehkordi; Ahmed T Ahmed; Sudeepa Bhattacharyya; Xianlin Han; Rebecca A Baillie; Matthias Arnold; Michelle K Skime; Lisa St John-Williams; M Arthur Moseley; J Will Thompson; Gregory Louie; Patricio Riva-Posse; W Edward Craighead; William McDonald; Ranga Krishnan; A John Rush; Mark A Frye; Boadie W Dunlop; Richard M Weinshilboum; Rima Kaddurah-Daouk
Journal:  Transl Psychiatry       Date:  2021-03-02       Impact factor: 6.222

Review 6.  Adaptation of Lipid Profiling in Depression Disease and Treatment: A Critical Review.

Authors:  Bruno Pinto; Tiago Conde; Inês Domingues; M Rosário Domingues
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

Review 7.  Carnitine and Depression.

Authors:  Ting Liu; Kunhong Deng; Ying Xue; Rui Yang; Rong Yang; Zhicheng Gong; Mimi Tang
Journal:  Front Nutr       Date:  2022-03-14

8.  Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease.

Authors:  Emrin Horgusluoglu; Ryan Neff; Won-Min Song; Minghui Wang; Qian Wang; Matthias Arnold; Jan Krumsiek; Beatriz Galindo-Prieto; Chen Ming; Kwangsik Nho; Gabi Kastenmüller; Xianlin Han; Rebecca Baillie; Qi Zeng; Shea Andrews; Haoxiang Cheng; Ke Hao; Alison Goate; David A Bennett; Andrew J Saykin; Rima Kaddurah-Daouk; Bin Zhang
Journal:  Alzheimers Dement       Date:  2021-11-10       Impact factor: 16.655

9.  Blood metabolic signatures of hikikomori, pathological social withdrawal.

Authors:  Daiki Setoyama; Toshio Matsushima; Kohei Hayakawa; Tomohiro Nakao; Shigenobu Kanba; Dongchon Kang; Takahiro A Kato
Journal:  Dialogues Clin Neurosci       Date:  2022-06-01

10.  Lipidomics in Major Depressive Disorder.

Authors:  Andreas Walther; Carlo Vittorio Cannistraci; Kai Simons; Claudio Durán; Mathias J Gerl; Susanne Wehrli; Clemens Kirschbaum
Journal:  Front Psychiatry       Date:  2018-10-15       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.